COMFORT LAUNCH BY VERGENCE NATURALS EXCEEDS EXPECTATIONS

October 11, 2018    |    Abattis Bioceuticals

VANCOUVER, BRITISH COLUMBIA / December 11, 2018 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to provide an update on the recent soft-launch of its cannabinoid-infused nutraceutical Comfort (“Comfort”) through the Company’s wholly-owned subsidiary, Vergence Naturals (“Vergence”), on Cyber-Monday, November 26, 2018.

“The launch was an outstanding success” according to Logistics Coordinator Mark Taylor of TandT Marketing. “Our goals for the soft launch were to test the ordering, payment and fulfillment systems by opening the e-commerce platform for only a few minutes. The immediate orders from Canadian and USA customers flooded the portal and demonstrated the need for greater bandwidth on both the ComfortByVergence.com and ComfortByVergence.ca e-commerce websites. Because of this, the sites were taken down to be re-tooled and are ready for this year’s holiday shopping season.”

Canada One Communications Inc. (“Canada One”), an Abattis media partner, quotes WorkArea.com in selecting Monday as the best day for e-commerce site sales, “The trend is that people shop online more on Mondays. Online shoppers love Mondays. The first day of the typical workweek produces more online retail sales from more shoppers who converted at a higher rate. Mondays generated over 16% of weekly revenue on average. Revenue generated on Mondays is 10% higher than Sunday, the second-best revenue generator.”

These statements are supported by Jelly Marketing, a Canadian social media and digital advertising firm located in Vancouver, BC. Jelly Marketing is another media partner for Vergence and Comfort. Jelly manages the Canadian digital advertising and Social Media marketing. “We will use the data collected in the test-window on Cyber-Monday to orchestrate a full digital and social media blitz for Comfort on the ComfortByVergence.ca website beginning on Monday, December 10.”

The orders for Comfort were predominantly Canadian, with orders from the United States representing 42% of sales. Commenting on the sales balance for this revolutionary product, Steve Syatt of SSA Public Relations (“SSAPR”) in Los Angeles, California noted the openness of Canadians to using cannabis-like substances for to manage pain. “The long history of medical Cannabis use in Canada has generated an acceptance not yet seen in every state in the United States. So, we are focusing on the message, ‘Cannabis without the Cannabis’ as Comfort contains phytocannabinoids from non-cannabis plants.” SSAPR is managing the Social Media and Digital Advertising for ComfortByVergence.com in the United States. “I am excited to join with Abattis in the establishment of Vergence, as an innovative health and wellness brand. Comfort uniquely blends phytocannabinoids from non-cannabis plant species to deliver safe and effective relief from occasional pain. We look forward to sharing this extraordinary remedy to adults throughout North America,” said Naturopath Brazos Minshew, President of the Abattis Medical Advisory Board.

“Mr. Minshew has worked tirelessly throughout his distinguished career in medicine to create herbal remedies focusing on the endocannabinoid system and phytocannabinoid science. Comfort is the result of Mr. Minshew’s intense experience in this critically important area of wellness and we are proud to work together to introduce his latest achievement to the public,” said Abattis’ President and CEO, Rob Abenante.
The extraordinary response to the soft-launch demonstrates the Company’s ability to effectively execute a successful product launch as well as pointing out the significant demand for Comfort in both the Canadian and United States marketplaces as the cannabis industry continues to develop.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to applicable laws of Canada and foreign jurisdictions.

ON BEHALF OF THE BOARD,

ABATTIS BIOCEUTICALS CORP,

“Rob Abenante”

Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com

For inquiries please contact (808) 650-3007 or at investors@abattis.com.  Abattis IR is managed by Canada One Communications Inc.

About Canada One Communications Inc.

Canada One is a full-service Investor Relations and Marketing company that focuses on both private and public sectors within the Canadian markets. Canada One offers timely responses to all investor inquiries over several mediums and effective, thorough market awareness programs that are specifically designed to maximize exposure and bring value to shareholders. Canada One’s dedicated and experienced team strives to promote client information to the public and educate potential investors on the various developments of its clients. From basic phone-call and email investor correspondence, to full-scale comprehensive marketing packages which includes industry analysis, website development, corporate videos and other marketing programs, Canada One provides a full suite of services that are fully compliant with Canadian securities regulations. Canada One is driven by an uncompromising dedication to provide publicly listed and private companies with across-the-board investor relations and marketing solutions, directly translating these services into organic growth and increased market value of its valued clients.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words including but not exclusive to “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding the global vaporizer market, the success of the marketing and sales of Abattis Vaporizers, and anticipation of the vaporizer market gaining worldwide popularity. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.